Mr. Miguel Martin reports

AURORA CANNABIS ANNOUNCES THE ALBERTA SECURITIES COMMISSION HAS DISMISSED CURALEAF'S APPLICATION AND RULED IN FAVOUR OF THE COMPANY'S AT-THE-MARKET PROGRAM

The application made by Curaleaf Holdings Inc. to halt Aurora Cannabis Inc.'s at-the-market (ATM) program has been dismissed by the Alberta Securities Commission.

This positive result supports Aurora's view that Curaleaf's actions were simply to distract shareholders from the fundamental issue before them: Curaleaf's hostile bid significantly undervalues Aurora and seeks to acquire Aurora's cash, unique EU-GMP (European Union good manufacturing practice) assets, global growth platform and future upside at a discount.

"Aurora's ATM program was publicly disclosed well before the hostile bid and was established to support legitimate accretive and strategic opportunities," said Miguel Martin, executive chairman and chief executive officer of Aurora. "We believe this unsuccessful application distracts from the fundamental shortcomings of Curaleaf's revised hostile bid."

"Shareholders should remain focused on the central issue: Curaleaf's revised hostile bid is inadequate and does not reflect Aurora's value or future potential. The board remains focused on maximizing value for Aurora shareholders and continues to unanimously recommend that they reject the revised hostile bid and take no action while all available strategic alternatives are considered," concluded Mr. Martin.

Aurora publicly announced the ATM program in February, 2026, more than six months before Curaleaf launched its hostile bid. The program was established to provide Aurora with flexibility to pursue strategic and accretive opportunities, including increased cultivation capacity and M&A (merger and acquisition) opportunities.

On Oct. 14, Aurora's board of directors filed a notice of change to directors circular, which unanimously recommended that shareholders reject Curaleaf's revised hostile bid by simply taking no action and not tendering their shares. The board unanimously recommends that any Aurora shareholders who have tendered their shares to the hostile bid withdraw those shares.

A notice of change to the directors circular providing the full details concerning the board's recommendation, including the reasons to reject the revised hostile bid and additional details in respect of the continuing strategic alternatives process, is available on the company's special website, on SEDAR+ and on EDGAR.

Shareholder assistance

Shareholders with questions about the hostile bid or who would like to receive continuing updates may contact Kingsdale Advisors, Aurora's strategic advisor and information agent, at toll-free (within North America) 1-800-749-9052, call or text 416-623-4172, or e-mail contactus@kingsdaleadvisors.com.

About Aurora Cannabis Inc.

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia and New Zealand with a portfolio of trusted, leading brands, including Aurora, MedReleaf, Pedanios, IndiMed, San Raf and Whistler Medical Marijuana Corporation. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis.

Aurora's common shares trade on the Nasdaq Stock Market and Toronto Stock Exchange under the symbol ACB.

Aurora has filed a solicitation/recommendation statement on Schedule 14D-9F with the U.S. Securities and Exchange Commission (SEC), which includes a directors circular, dated Sept. 1, 2026, as amended by the notice of change. Investors are urged to read this document and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, when they become available, before making any investment decision with respect to the hostile bid. The hostile bid is made for the securities of a Canadian issuer and while the hostile bid is subject to disclosure requirements of Canada, investors should be aware that these requirements are different from those of the United States. The enforcement by investors of civil liabilities under the U.S. federal securities laws may be affected adversely by the fact that the issuer is located in Canada, and that some or all of its officers and directors are residents of Canada.

We seek Safe Harbor.